3-phenylaminoguanidine hydroiodide | 56204-41-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-phenylaminoguanidine hydroiodide
• 英文别名: 3-phenyl-1-aminoguanidine hydroiodide；1-amino-2-phenylguanidine;hydroiodide
• CAS: 56204-41-2
• 化学式: C₇H₁₀N₄*HI
• mdl: MFCD00186638
• 分子量: 278.096
• InChiKey: LSWGLZIOXCIOMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.72
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.4
• 氢给体数：
  4
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-phenylaminoguanidine hydroiodide 在 盐酸 、 sodium carbonate 、 silver nitrate 、 sodium nitrite 作用下， 以 水 、 硝酸 为溶剂， 生成 莫非那
  参考文献：
  名称：

  Tetrazole-substituted urea acat inhibitors

  摘要：

  新型ACAT抑制剂在治疗动脉粥样硬化方面非常有用，这些抑制剂是噻唑酮取代脲类化合物。

  公开号：

  US05362744A1
• 作为产物：
  描述：

  S-methyl-N-phenylisothiourea hydroiodide 在 一水合肼 作用下， 以 乙腈 为溶剂， 反应 48.0h， 生成 3-phenylaminoguanidine hydroiodide
  参考文献：
  名称：

  合成 3,6-二氨基取代基 1,2,4-Triazin-5(2H)-one / 3,6-二氨基取代的 1,2,4-Triazin-5(2H)-one 的合成和性质

  摘要：

  超声促进 N1-氨基-N2-芳基甲基-（或芳基-）胍 2 与 2-氨基-2-硫代乙酸乙酯的环缩合反应得到新型 3,6-二氨基取代的 1,2,4-triazin-5(2H) )- 4 个中高产量。化合物 4 的酰化在环位置 2 发生区域选择性，推测可能是由于分子内氢键的形成。根据这一假设，6-氨基-3-[苄基（甲基）氨基]-1,2,4-triazin-5(2H)-one (9) 的乙酰化没有提供 2-乙酰衍生物 11，但而不是 6-乙酰胺衍生物 10. 图形摘要合成和特征 3,6-二氨基取代基 1,2,4-Triazin-5(2H)-one / 3,6-二氨基取代的 1,2,4- 的合成和性质Triazin-5(2H)-ones

  DOI：

  10.1515/znb-2010-0506

文献信息

• Hydrazono-5.beta., 14.beta.-androstane derivatives active on the
  申请人：SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

  公开号：US05538960A1

  公开（公告）日：1996-07-23

  The present invention relates to new 17-hydrazonomethyl- and 17-hydrazono-14.beta.-hydroxy-5.beta.-androstane derivatives active on the cardiovascular system, to a process for their preparation and to pharmaceutical compositions containing same for the treatment of cardiovascular disorders, such as heart failure and hypertension.

  本发明涉及对心血管系统活性的新17-酰肼甲基和17-酰肼基-14-β-羟基-5-β-雄烷衍生物，以及它们的制备方法和含有相同物质的用于治疗心血管疾病，如心力衰竭和高血压的药物组合物。
• New hydrazono-5-beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same
  申请人：Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP0583606A2

  公开（公告）日：1994-02-23

  17-Hydrazonomethyl- and 17-hydrazone-14β-hydroxy-5β-androstane derivatives of general formula (I): wherein the symbols A, --- and Y have the meaning as indicated in the specification. Processes for producing these derivatives, pharmaceutical compositions containing them as well as their use are also disclosed.

  通式（I）的 17-肼甲基-和 17-腙-14β-羟基-5β-雄甾烷衍生物： 其中符号 A、---和 Y 的含义如说明书所示。此外，还公开了这些衍生物的生产工艺、含有这些衍生物的药物组合物及其用途。
• New 17-iminomethylalkenyl-5beta-14beta-androstane and 17-iminoalkyl-5beta-14beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same
  申请人：Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP0659761A2

  公开（公告）日：1995-06-28

  The present invention provides 17-Iminomethylalkenyl- and 17-iminoalkyl-14β-hydroxy-5β-androstane derivatives of general formula (I): wherein: the symbol means a or configuration or a Z or E configuration; A represents (CH2)m or -(CH = CH)n-; m represents an integer number from 1 to 6; n represents an integer number from 1 to 3. R1 represents hydrogen, C2-C4 alkyl unsubstituted or substituted by NR4R5 wherein R4, R5 which may be the same or different, represent hydrogen, C1-C4 alkyl or R4 and R5 may form, taken together with the nitrogen atom, a five- or six-membered heterocyclic ring optionally containing one or more further heteroatoms selected from oxygen and nitrogen; R2 represents hydrogen or hydroxy; R3 represents NHC(=X)NR6Ry or OR8 wherein R6, R7 which may be the same or different, represent hydrogen, methyl or C2-C4 alkyl unsubstituted or substituted by NR4 R5 wherein R4 and R5 have the previously defined meanings; R8 represents hydrogen; methyl; C2-C6 alkyl, unsubstituted or substituted by one or more NR4R5 or NHC(=NH)NH2, wherein R4 and R5 have the previously defined meanings; X represents O, S or NR9; R9 represents hydrogen, methyl, C2-C4 alkyl, C2-C4 acyl or phenyl, where the C2-C4 alkyl, C2-C4 acyl are unsubstituted or substituted by NR4 R5, wherein R4 and R5 have the previously defined meanings; and R6, R7, R9 taken two by two may form, together with the heteroatoms they are linked to, and where possible, a five- or six- or seven-membered heterocyclic ring.

  本发明提供 通式(I)的17-亚甲基烯基和17-亚氨基烷基-14β-羟基-5β-雄甾烷衍生物： 其中 符号表示或构型或 Z 或 E 构型； A 代表 (CH2)m 或 -(CH = CH)n-； m 代表 1 至 6 的整数； n 代表 1 至 3 的整数。 R1 代表氢、未取代的 C2-C4 烷基或被 NR4R5 取代的 C2-C4 烷基，其中 R4、R5 可以相同或不同，代表氢、C1-C4 烷基或 R4 和 R5 可与氮原子一起形成一个五元或六元杂环，该杂环可任选含有一个或多个选自氧和氮的杂原子； R2 代表氢或羟基； R3 代表 NHC(=X)NR6Ry 或 OR8，其中 R6、R7 可以相同或不同，代表氢、甲基或未取代的 C2-C4 烷基或被 NR4 R5 取代的 C2-C4 烷基，其中 R4 和 R5 具有前面定义的含义； R8 代表氢；甲基；未被一个或多个 NR4R5 取代或取代的 C2-C6 烷基或 NHC(=NH)NH2，其中 R4 和 R5 具有前面定义的含义； X 代表 O、S 或 NR9； R9 代表氢、甲基、C2-C4 烷基、C2-C4酰基或苯基，其中 C2-C4 烷基、C2-C4酰基未被 NR4R5 取代或被 NR4R5 取代，其中 R4 和 R5 具有前面定义的含义；以及 R6、R7、R9 与它们相连的杂原子可组成五元或六元或七元杂环。
• Kramer, C.-R.; Schelenz, Th.; Stein, J., Zeitschrift fur Physikalische Chemie (Leipzig), 1984, vol. 265, # 5, p. 849 - 864
  作者：Kramer, C.-R.、Schelenz, Th.、Stein, J.

  DOI：——

  日期：——
• Synthesis and Quantitative Structure−Activity Relationships of 17β-(Hydrazonomethyl)-5β-androstane-3β,14β-diol Derivatives That Bind to Na⁺,K⁺-ATPase Receptor
  作者：Luisa Quadri、Alberto Cerri、Patrizia Ferrari、Elena Folpini、Massimo Mabilia、Piero Melloni

  DOI：10.1021/jm950806n

  日期：1996.1.1

  A series of 17 beta-(hydrazonomethyl)-5 beta-androstane-3 beta,14 beta-diol derivatives was synthesized and evaluated in the displacement of [H-3]ouabain binding from Na+,K+-ATPase. The data were explored with multiple linear regression and partial least-squares to find possible quantitatives structure-activity relationships. Good correlations were found between binding to the receptor and van der Waals volumes or molar refractivities of the 17 beta-hydrazonomethyl substituents and pK(a) values of the compounds. Equivalent results were obtained using the proton affinity (calculated using MOPAC) of the hydrazone residues instead of experimental pK(a). As basicity or related electronic factors of the substituents explain a significant portion of the observed changes in the activity, an ion-pair interaction between a carboxylate residue of the enzyme and the protonated 17 beta-hydrazonomethyl group, as postulated by Thomas, plays an important role in the interaction of the ligand to the Na+,K+-ATPase receptor.